Breaks Categories: News

MondaySep 11, 2017 10:05 am

CBDNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Retains Biopsy, LLC to Provide Leadership in Growth and E-Commerce

Market analysis company ChineseInvestors.com, Inc. (OTCQB: CIIX) this morning announced its retention of Biopsy, LLC, managed by bestselling author Chris J. Snook, to provide leadership in growth and e-commerce. Effective September 1, 2017, Biopsy, LLC will serve as the architect of the digital infrastructure and go-to-market strategy for ChineseInvestors.com, Inc. and its subsidiaries, reporting directly to the companies’ management teams. “ChineseInvestors.com, Inc. is fortunate to be able to contract with Biopsy, LLC as Chris' unique skill and experience will enhance the Company's ability to effectively emerge as a leader in the CBD Biotechnology Industry, while also strengthening and expanding the…

Continue Reading

MondaySep 11, 2017 9:11 am

CBDNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Provides Update on Data Linking THC to Decrease in Aβ40 Protein Production

India Globalization Capital, Inc. (NYSE American: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced compelling in vitro data compiled from genetically engineered cell lines showing that, at varying concentrations of THC, the production of Aβ40 protein decreases by as much as 50 percent over a 48-hour period. This is particularly noteworthy for patients with Alzheimer’s disease, as the condition often results in an imbalance of Aβ plaque that is believed to be toxic to nerve cells. This data, compiled by Dr. Chuanhai Cao, an IGC senior advisor and associate professor of pharmaceutical…

Continue Reading

FridaySep 08, 2017 9:14 am

CBDNewsBreaks – Leafbuyer Technologies (LBUY) Enters Deal with Leading Dispensary Chain

Leafbuyer Technologies, Inc. (OTC: LBUY), a leading cannabis technology platform known as the premier cannabis deals network, is adding Rocky Road Remedies to its client base. Leafbuyer will provide a suite of services to Rocky Road Remedies, a leading cannabis dispensary chain with six locations in Colorado. Leafbuyer drives business to dispensaries and product clients through its online platform, Leafbuyer.com In the news release, Leafbuyer vice president of business development and co-founder Mark Breen said, “We are committed to driving business to our customer base as well as providing the best deals for the consumer in the cannabis industry.” To…

Continue Reading

ThursdaySep 07, 2017 1:09 pm

CBDNewsBreaks – Organigram (TSX.V: OGI) (OTCQB: OGRMF) Enters into MOU for Microwave Assisted Extraction Technique Development

Organigram Holdings Inc. (TSX.V: OGI) (OTCQB: OGRMF) will jointly develop an industry leading method of microwave extraction of cannabinoid extracts from marijuana plants with the New Brunswick Innovation Research Chair in Medical Technologies (NBIRC), an initiative of the New Brunswick Innovation Fund (NBIF), it was announced Wednesday. A memorandum of understanding between Organigram Holdings Inc. and NBIRC details the project which will focus on developing a more efficient manner of extracting cannabinoids for use in extracts and edibles. The project will be led by Dr. J. R. Jocelyn Paré, holder of the NBIRC, the inventor of various Microwave-Assisted Processes forming…

Continue Reading

ThursdaySep 07, 2017 1:02 pm

CBDNewsBreaks – Cannabics Pharmaceuticals (CNBX) Files Patent Application for Sensitivity Tests of Cannabinoids on Patient Derived Tumor Biopsies and CTCs

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) has filed an extensive provisional patent application with the U.S. Patent & Trademark Office on a new “Method for Sensitivity Tests of Cannabinoids on Patient Derived Tumor Biopsies and CTCs.” The method, developed by Cannabics Pharmaceuticals, expands the company’s proprietary technology of personalization of cannabinoid medicine. The current invention pertains to a combined method and system for assessing the sensitivity of a variety of cannabinoid-based treatment modalities on patient-derived primary tumor biopsies as well as blood circulating tumor cells (CTC). In the news release, Dr. Moran Grinberg, Cannabics Pharmaceuticals Vice President of Research and Development,…

Continue Reading

ThursdaySep 07, 2017 12:58 pm

CBDNewsBreaks – EVIO, Inc.’s (SGBYD) EVIO Labs Division Enters Cannabis Testing License Agreement in Colorado

EVIO, Inc. (OTCQB: SGBYD) this morning said that its cannabis testing division, EVIO Labs, has entered into an agreement with Phytatech CO, LLC to license its brand and cannabis technology in Colorado. Per the agreement, Phytatech will now operate under the EVIO Labs brand. "As we continue our mission to become the industry’s largest cannabis testing company, with operations in California, Oregon, Massachusetts, and Florida, EVIO is honored to now offer its accredited testing services to Colorado,” EVIO chief executive officer William Waldrop stated in the news release. To view the full press release, visit: http://cnw.fm/UgRy3 About EVIO EVIO, Inc.…

Continue Reading

ThursdaySep 07, 2017 9:31 am

CBDNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Names Barry Fishman as New CEO

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) this morning announced the appointment of Barry Fishman as its new chief executive officer, effective October 1, 2017. Fishman brings nearly two decades of experience as a business leader to the ABcann team, having most recently served as CEO of international specialty pharmaceutical company Merus Labs. Under his leadership, Merus’s sales and EBITDA grew at a CAGR of greater than 50 percent, leading to the company’s acquisition by Norgine B.V. in July 2017 for total considerations of roughly $342 million. “Barry's proven experience as a CEO of complex, highly-regulated organizations with international operations…

Continue Reading

WednesdaySep 06, 2017 9:41 am

CBDNewsBreaks – SinglePoint, Inc. (SING) Announces Acquisition of Dr. FeelGood

Specialized holding company SinglePoint, Inc. (OTC: SING) this morning announced its acquisition of Dr. FeelGood, a profitable cannabis distribution company headquartered in Phoenix, Arizona. Per the terms of the agreement, SinglePoint will acquire a 51 percent stake in Dr. FeelGood in exchange for cash and stock, allowing SinglePoint to recognize all of the company’s revenue and effectively strengthening its revenue-by-acquisition strategy. “We are very excited for the success of this acquisition,” Greg Lambrecht, CEO of SinglePoint, stated in the news release. “The acquisition of Dr. FeelGood is the third acquisition of the year. SinglePoint's revenue has dramatically increased, which through…

Continue Reading

TuesdaySep 05, 2017 12:09 pm

CBDNewsBreaks – Easton Pharmaceuticals, Inc. (EAPH) Marks C$1M Paid toward Alliance Group Partnership Agreement

Easton Pharmaceuticals (OTC: EAPH) this morning said it has advanced C$1 million in payments to Alliance Group pursuant to its previously announced closing agreement with Canada-based 124123 Ontario Inc. (O/A - Alliance Group). In turn, Alliance has executed C$8 million aggregate toward the LOI contract on its 90 acres of zoned industrial land. Easton has now paid a total of C$1 million out of the C$1.3 million required to acquire a 50% stake in 45 acres of agriculturally zoned land north of Toronto, Ontario, Canada, as well as a business to cultivate, produce and facilitate the sale of its production…

Continue Reading

ThursdayAug 31, 2017 9:20 am

CBDNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Announces Clinical Study of High Absorption TurboCBD™ Product

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a company engaged in licensing proprietary technology for the delivery of bioactive compounds, this morning announced the world’s first clinical study on human volunteers of cannabidiol (CBD) within Lexaria’s TurboCBD™ product. The study, which aims to evaluate the effects of TurboCBD™ on both cardiovascular health and cognitive function, will have a double-blind and placebo controlled cross-over design measuring effects after a single dose, as well as seven days of daily dosing, in 24 volunteers. “Lexaria is proud to be advancing our collective knowledge of the benefits of CBD specifically showcasing the benefits of…

Continue Reading